AU708886B2 - Tumor necrosis factor (TNF) inhibiting pharmaceuticals - Google Patents

Tumor necrosis factor (TNF) inhibiting pharmaceuticals Download PDF

Info

Publication number
AU708886B2
AU708886B2 AU69420/96A AU6942096A AU708886B2 AU 708886 B2 AU708886 B2 AU 708886B2 AU 69420/96 A AU69420/96 A AU 69420/96A AU 6942096 A AU6942096 A AU 6942096A AU 708886 B2 AU708886 B2 AU 708886B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
compound
branched
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69420/96A
Other languages
English (en)
Other versions
AU6942096A (en
Inventor
Ruth Gallily
Raphael Mechoulam
Esther Shohami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU6942096A publication Critical patent/AU6942096A/en
Application granted granted Critical
Publication of AU708886B2 publication Critical patent/AU708886B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU69420/96A 1995-09-11 1996-09-10 Tumor necrosis factor (TNF) inhibiting pharmaceuticals Ceased AU708886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL115245 1995-09-11
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals
PCT/IL1996/000108 WO1997011668A2 (en) 1995-09-11 1996-09-10 TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS

Publications (2)

Publication Number Publication Date
AU6942096A AU6942096A (en) 1997-04-17
AU708886B2 true AU708886B2 (en) 1999-08-12

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69420/96A Ceased AU708886B2 (en) 1995-09-11 1996-09-10 Tumor necrosis factor (TNF) inhibiting pharmaceuticals

Country Status (9)

Country Link
US (3) US5932610A (https=)
EP (1) EP0876143B1 (https=)
JP (1) JP2000500737A (https=)
AT (1) ATE331503T1 (https=)
AU (1) AU708886B2 (https=)
CA (1) CA2231764A1 (https=)
DE (1) DE69636308T2 (https=)
IL (1) IL115245A (https=)
WO (1) WO1997011668A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU3910700A (en) 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
CA2387764A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
EP1267903A4 (en) * 2000-02-08 2003-08-06 Pharmacia Corp METHOD FOR TREATING GLAUCOMA
CA2781858C (en) * 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
DE60125541T2 (de) * 2000-06-22 2007-10-11 Pharmos Corp. Neue nicht psychotropische cannabinoide
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
EP1361876A4 (en) * 2001-01-26 2004-03-31 Univ Connecticut NEW CANNABIMIMETIC LIGANDS
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
JP4312594B2 (ja) * 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット 新規な二環式及び三環式カンナビノイド
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
CA2507815A1 (en) * 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
CA2623723A1 (en) * 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
DE69636308T2 (de) 2007-05-31
JP2000500737A (ja) 2000-01-25
ATE331503T1 (de) 2006-07-15
WO1997011668A3 (en) 1997-05-15
EP0876143A2 (en) 1998-11-11
US6545041B2 (en) 2003-04-08
WO1997011668A2 (en) 1997-04-03
DE69636308D1 (de) 2006-08-10
AU6942096A (en) 1997-04-17
IL115245A (en) 2002-12-01
IL115245A0 (en) 1995-12-31
EP0876143A4 (en) 2001-06-27
CA2231764A1 (en) 1997-04-03
EP0876143B1 (en) 2006-06-28
US20020049245A1 (en) 2002-04-25
US6331560B1 (en) 2001-12-18
US5932610A (en) 1999-08-03

Similar Documents

Publication Publication Date Title
AU708886B2 (en) Tumor necrosis factor (TNF) inhibiting pharmaceuticals
US5284867A (en) NMDA-blocking pharmaceutical compositions
US4507323A (en) Treatment of psychosexual dysfunctions
AU2002225026B2 (en) Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
JP6076737B2 (ja) 高血圧症の防止及び治療のための組成物並びに方法
JP2852043B2 (ja) 安定化薬剤組成物
JP3114895B2 (ja) 炎症性疾患の処置のための薬剤調製物
CN108472275A (zh) 治疗缺血性中风的组合物及方法
US5175187A (en) Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
CA2136977A1 (en) _-8-tetrahydro-cannabinol as antiemetic
KR20260011783A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
KR20250152044A (ko) 멜리사엽 분획 추출물 및 이를 포함하는 신규 약학적 조성물
US6916849B2 (en) Compositions for improving lipid content in the blood
US20090068143A1 (en) Orally effective cannabinoid analogs
IL92238A (en) ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
US20240269104A1 (en) Method for treating parkinson's disease
JPH03271226A (ja) 腎炎治療剤
US5252600A (en) Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
De Kozak et al. Ginkgo biloba extract (EGb 761) and a platelet-activating factor antagonist protect the retina in experimental autoimmune uveoretinitis
JPH07165588A (ja) 脳機能改善剤
AU2023327823A1 (en) Cannabidiol for use in treating or preventing recurrent pericarditis
CN118892483A (zh) 一种mpo酶抑制剂在制备预防和/或治疗神经炎症疾病药物中的应用
CN121714621A (zh) 香青兰总黄酮在制备预防或治疗自身免疫性脱髓鞘疾病药物中的应用
CN121754576A (zh) 滨蒿总黄酮在制备预防或治疗自身免疫性脱髓鞘疾病药物中的应用
JP2001253825A (ja) 帯状疱疹後神経痛用鎮痛剤